Related Experiment Video
Updated: Feb 19, 2026
07:25
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
13.9K
[Consensus on castration-resistant prostate cancer management in Spain.]
Antonio Alcaraz1, Luís Martínez-Piñeiro2, Alfredo Rodríguez3
1Hospital Clínic. Universitat de Barcelona. Barcelona. España.
Archivos Espanoles De Urologia
|November 4, 2017
Summary
Spanish experts developed consensus recommendations for managing castration-resistant prostate cancer (CRPC). Guidelines cover diagnosis, imaging, progression, and treatment sequencing to standardize care and improve patient quality of life.
Area of Science:
- Urology
- Oncology
- Medical Practice Guidelines
Background:
- Castration-resistant prostate cancer (CRPC) management lacks standardization in Spain.
- A panel of 18 Spanish urology experts convened to address this gap.
Framework:
- A modified Delphi process with two rounds and a consensus meeting was employed.
- 106 clinical questions were addressed, covering CRPC definition, diagnosis, symptoms, progression, and treatment.
Implementation:
- Recommendations address imaging techniques, defining CRPC progression, and managing M0 and M1 disease.
- Bone scans are recommended with caveats; MRI offers higher sensitivity but at greater cost.
- First-line therapy for M1 CRPC involves enzalutamide/abiraterone and/or docetaxel, guided by symptom burden.
Implications:
- Standardized CRPC management aims to improve patient quality of life.
- These recommendations provide a framework for Spanish physicians to tailor patient care.
- The consensus promotes appropriate use of imaging and timely treatment sequencing.
